ARTICLE | Clinical News
VGX-6150: Phase I started
October 28, 2013 7:00 AM UTC
Inovio said its VGX affiliate began an open-label, dose-escalation, Korean Phase I trial to evaluate 4 monthly vaccinations with 1, 3 and 6 mg VGX-6150 in 18 patients with chronic HCV infection who fa...